FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Molineaux Christopher P.					2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]									eck all applic	ationship of Reportin all applicable) Director		10% Ov	vner		
	`	ERAPEUTICS, I	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2021								below)	(give title		Other (s below)				
(Street) WAYNE (City)	P.F	A	19087 (Zip)		4. 11	Lin								Line	ndividual or Joint/Group Filing (Check Applicable b) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
D			Date	nsaction h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		r, Transaction Disposed Code (Instr. 5)		rities Acquired (A) ad Of (D) (Instr. 3, 4		A) or i, 4 and	5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	Form (D) or	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	,	Amount	(A) or (D) Price		Price	Transact	Transaction(s) (Instr. 3 and 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e O S Fe Ily D OI (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	or Nu of	ımber						
Stock Option (Right to Buy)	\$21.9	06/03/2021			A		12,250		(1)(2)	06/	/02/2031	Commo Stock	12	2,250	\$0.00	12,250)	D		
Restricted Stock Units	(3)	06/03/2021			A		3,356		(1)(4)		(4)	Commo Stock	¹ 3	,356	\$0.00	3,356		D		

Explanation of Responses:

- 1. This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy.
- 2. The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date.
- 3. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 4. The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date.

Remarks:

/s/ Mark Ballantyne, Attorney-

06/04/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.